Logo image of ISEE

IVERIC bio Inc (ISEE) Stock Fundamental Analysis

NASDAQ:ISEE - Nasdaq - US46583P1021 - Common Stock - Currency: USD

39.95  +0.15 (+0.38%)

After market: 39.94 -0.01 (-0.03%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ISEE. ISEE was compared to 571 industry peers in the Biotechnology industry. While ISEE seems to be doing ok healthwise, there are quite some concerns on its profitability. ISEE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ISEE has reported negative net income.
ISEE had a negative operating cash flow in the past year.
In the past 5 years ISEE reported 4 times negative net income.
ISEE had a negative operating cash flow in each of the past 5 years.
ISEE Yearly Net Income VS EBIT VS OCF VS FCFISEE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M

1.2 Ratios

The profitability ratios for ISEE are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISEE Yearly ROA, ROE, ROICISEE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 100 -100 200 300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ISEE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ISEE Yearly Profit, Operating, Gross MarginsISEE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

ISEE has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ISEE is higher compared to a year ago.
ISEE Yearly Shares OutstandingISEE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
ISEE Yearly Total Debt VS Total AssetsISEE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

An Altman-Z score of 22.00 indicates that ISEE is not in any danger for bankruptcy at the moment.
ISEE has a better Altman-Z score (22.00) than 94.41% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that ISEE is not too dependend on debt financing.
ISEE has a Debt to Equity ratio of 0.20. This is in the lower half of the industry: ISEE underperforms 69.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 22
ROIC/WACCN/A
WACCN/A
ISEE Yearly LT Debt VS Equity VS FCFISEE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M 400M

2.3 Liquidity

ISEE has a Current Ratio of 15.53. This indicates that ISEE is financially healthy and has no problem in meeting its short term obligations.
ISEE has a Current ratio of 15.53. This is amongst the best in the industry. ISEE outperforms 87.97% of its industry peers.
ISEE has a Quick Ratio of 15.53. This indicates that ISEE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ISEE (15.53) is better than 87.97% of its industry peers.
Industry RankSector Rank
Current Ratio 15.53
Quick Ratio 15.53
ISEE Yearly Current Assets VS Current LiabilitesISEE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ISEE have decreased strongly by -55.75% in the last year.
EPS 1Y (TTM)-55.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ISEE will show a very strong growth in Earnings Per Share. The EPS will grow by 33.86% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.05%
EPS Next 2Y6.29%
EPS Next 3Y25.52%
EPS Next 5Y33.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ISEE Yearly Revenue VS EstimatesISEE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
ISEE Yearly EPS VS EstimatesISEE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ISEE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ISEE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ISEE Price Earnings VS Forward Price EarningsISEE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ISEE Per share dataISEE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

ISEE's earnings are expected to grow with 25.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.29%
EPS Next 3Y25.52%

More info and screens

0

5. Dividend

5.1 Amount

ISEE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IVERIC bio Inc

NASDAQ:ISEE (7/10/2023, 8:00:03 PM)

After market: 39.94 -0.01 (-0.03%)

39.95

+0.15 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10 2023-05-10/bmo
Earnings (Next)07-24 2023-07-24/bmo
Inst Owners0.92%
Inst Owner Change0%
Ins Owners0.05%
Ins Owner Change0%
Market Cap5.51B
Analysts52.86
Price Target39.88 (-0.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.08%
Min EPS beat(2)-22.88%
Max EPS beat(2)-11.29%
EPS beat(4)1
Avg EPS beat(4)-11.73%
Min EPS beat(4)-27.83%
Max EPS beat(4)15.07%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.38%
PT rev (3m)25.45%
EPS NQ rev (1m)-3.77%
EPS NQ rev (3m)-2.87%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.55
P/tB 11.55
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)-1.32
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS3.46
TBVpS3.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 456.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.53
Quick Ratio 15.53
Altman-Z 22
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-55.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.76%
EPS Next Y-21.05%
EPS Next 2Y6.29%
EPS Next 3Y25.52%
EPS Next 5Y33.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.94%
EBIT Next 3Y31.5%
EBIT Next 5Y39.62%
FCF growth 1Y-127.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.44%
OCF growth 3YN/A
OCF growth 5YN/A